- Home
- ELVN vs JFR Comparison
ELVN vs JFR Comparison
Compare ELVN & JFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- JFR
- Stock Information
- Founded
- ELVN 2016
- JFR 2004
- Country
- ELVN United States
- JFR United States
- Employees
- ELVN N/A
- JFR N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- JFR Trusts Except Educational Religious and Charitable
- Sector
- ELVN Health Care
- JFR Finance
- Exchange
- ELVN Nasdaq
- JFR Nasdaq
- Market Cap
- ELVN 1.2B
- JFR 1.3B
- IPO Year
- ELVN 2020
- JFR N/A
- Fundamental
- Price
- ELVN $20.61
- JFR $7.87
- Analyst Decision
- ELVN Strong Buy
- JFR
- Analyst Count
- ELVN 5
- JFR 0
- Target Price
- ELVN $41.20
- JFR N/A
- AVG Volume (30 Days)
- ELVN 399.0K
- JFR 621.7K
- Earning Date
- ELVN 11-12-2025
- JFR 01-01-0001
- Dividend Yield
- ELVN N/A
- JFR 11.31%
- EPS Growth
- ELVN N/A
- JFR N/A
- EPS
- ELVN N/A
- JFR N/A
- Revenue
- ELVN N/A
- JFR N/A
- Revenue This Year
- ELVN N/A
- JFR N/A
- Revenue Next Year
- ELVN $20.05
- JFR N/A
- P/E Ratio
- ELVN N/A
- JFR N/A
- Revenue Growth
- ELVN N/A
- JFR N/A
- 52 Week Low
- ELVN $13.30
- JFR $7.61
- 52 Week High
- ELVN $29.79
- JFR $8.82
- Technical
- Relative Strength Index (RSI)
- ELVN 50.78
- JFR 34.57
- Support Level
- ELVN $20.10
- JFR $7.71
- Resistance Level
- ELVN $22.36
- JFR $8.15
- Average True Range (ATR)
- ELVN 0.98
- JFR 0.08
- MACD
- ELVN -0.01
- JFR -0.01
- Stochastic Oscillator
- ELVN 39.98
- JFR 37.20
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.